Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal
| Autor: | JA Erkens, Michiel W. van der Linden, Ron M. C. Herings, Connie Chen, Myrthe P. P. Sukel |
|---|---|
| Přispěvatelé: | Epidemiology and Data Science |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Databases Factual Demographics Gastrointestinal Diseases Epidemiology Analgesic Drug Prescriptions Arthritis Rheumatoid Cohort Studies Lactones Drug Utilization Review Internal medicine medicine Hospital discharge Humans Initial treatment Pharmacology (medical) Sulfones Practice Patterns Physicians' Medical prescription Rofecoxib Cyclooxygenase 2 Inhibitors business.industry Anti-Inflammatory Agents Non-Steroidal Proton Pump Inhibitors Middle Aged Pharmacoepidemiology Surgery Cardiovascular Diseases Cohort Drug and Narcotic Control Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Pharmacoepidemiology and Drug Safety, 17(1), 9-19. John Wiley and Sons Ltd Sukel, M P P, van der Linden, M W, Chen, C, Erkens, J A & Herings, R M C 2008, ' Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal ', Pharmacoepidemiology and Drug Safety, vol. 17, no. 1, pp. 9-19 . https://doi.org/10.1002/pds.1508 |
| ISSN: | 1053-8569 |
| DOI: | 10.1002/pds.1508 |
| Popis: | Purpose To compare treatment changes after the rofecoxib withdrawal with changes occurring normally and to re-assess 12 months afterwards. Methods The PHARMO database comprised medication and hospital discharge records of over 3 million inhabitants in the Netherlands. The Study cohort included chronic coxib users with a coxib prescription on 30th September 2004; the Reference cohort others with a coxib prescription on 1st June 2004. Initial treatment changes were based on first new prescription since cohort entry. Twelve-month changes were studied within the Study cohort only. Results The Study cohort (n = 6974) and Reference cohort (n = 5393) had similar demographics, stratified on type of coxib. In the Study cohort, 3341 (48%) initially stopped coxibs, of whom 1121 (16%) stopped all analgesic, versus 13 and 5% in the Reference cohort (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text